Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More than 110 pulmonologists, rheumatologists and radiologists and three international speakers focused on the latest scientific guidelines to improve the clinical outcomes for patients living with rare respiratory conditions at a Dubai event.
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2 Phase III trial also demonstrated
/PRNewswire/ -- EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults...
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopat...
The US Food and Drug Administration recently became the first regulatory authority to approve spesolimab as a treatment option for generalised pustular psoriasis (GPP) flares in adults.